The Volga muscle-invasive bladder cancer study might have matched Keynote-905.
ApexOnco Front Page
Recent articles
The company abandons lorigerlimab in ovarian cancer, and lowers its dose elsewhere.
But could toxicity be holding back filing plans?
Syndax scored the first menin approval, but Kura is first with a licensing deal.
A CD22-directed Car that has had several owners will next year deliver its most important dataset.
GEN1286/PRO1286 features among the latest industry projects to enter clinical trials.
The group touts a 72% ORR with SCIB1, but full Scope data have been pushed back into 2025.
A 5% response rate with IMA402 monotherapy seems unlikely to turn heads.